2.1 Population Health Promotion and Screening

The current FNP-BC Test Content Outline weights Assessment at 29 scored items (19%) through the October 18, 2026 administration and 26 scored items (17%) beginning October 30, 2026. The first official knowledge statement in that domain is evidence-based population health promotion and screening. The exam is not asking you to recite every interval from a laminated card. It is asking you to speak the language of net benefit in a defined population, pick the correct authority for the patient's age, and turn a grade into an offer, a selective discussion, or a decision to stop.

USPSTF grades are FNP planning language

The U.S. Preventive Services Task Force (USPSTF) writes recommendations for asymptomatic people in specified groups. A grade is not a personal order and it is not a diagnosis. It is a statement about certainty and magnitude of net benefit (benefit minus harm) for that population.

Affordable Care Act first-dollar coverage for preventive services generally tracks A and B recommendations. That is why stems often pair a letter with an ordering or counseling decision rather than asking you to name the grade in isolation. Grade C services (PSA discussion at 55–69, colorectal screening at 76–85, statin primary prevention when 10-year risk is 7.5% to <10%) are not “wrong” — they are preference-sensitive. Grade D examples worth knowing include PSA screening at 70 and older, cervical screening before 21, and ovarian-cancer screening with CA-125 or transvaginal ultrasound in average-risk women. An I statement is not a hidden D. Anxiety screening in adults 65 and older and starting a statin for primary prevention at 76 and older are I statements: you may still act, but you must say the evidence does not settle the balance.

Screening versus diagnostic testing

Screening is a test offered to a person who does not have signs or symptoms of the target condition, in order to find disease earlier than it would present. Diagnostic testing is ordered once a symptom, a sign, or an abnormal screen has already raised a hypothesis. The same machine can do both jobs. A mammogram in a 48-year-old with no breast complaint is screening (current USPSTF: biennial, ages 40–74, Grade B). A diagnostic mammogram after a palpable mass is not a “screen,” and a normal screening interval does not apply.

Two exam traps sit here. First, treating a positive screen as a diagnosis. A reactive HCV antibody is not chronic infection until HCV RNA is confirmed. A PHQ-2 of 3 is not major depression until you complete a diagnostic assessment and a suicide-risk review. A positive FIT is an indication for colonoscopy, not a colon-cancer diagnosis. Second, skipping a screen because the patient “looks well.” Screening exists precisely because early disease is silent. A third, quieter trap is counting a diagnostic CT done for hemoptysis as that year’s lung-cancer screening LDCT. Different protocol, different reading pathway, different follow-up — do not check the prevention box unless the study was performed and interpreted as a screen.

Population risk versus individual risk

USPSTF statements are written for average-risk populations defined by age, sex assigned at birth or screening anatomy, and a short list of risk factors (pack-years, ever-smoked, pregnancy). Individual patients can sit far above or below that average. A 42-year-old with a pathogenic BRCA1 variant does not live on the average-risk biennial-mammography pathway. A 68-year-old man who never smoked does not meet the Grade B criterion for AAA ultrasound. When a stem hands you a pedigree, a 30-pack-year history, prior CIN3, or current pregnancy, drop the average-risk table and reason from the individual risk.

Social determinants of health (SDOH) are a population lens that change who you screen, how you offer the test, and whether the result can be acted on. Economic stability, housing, food, transportation, insurance type, language access, neighborhood safety, and racism in care delivery do not receive USPSTF letter grades, but they determine uptake and follow-up. Ordering LDCT for an eligible uninsured patient without a navigation plan is an incomplete assessment. The October 30, 2026 TCO elevates SDOH and sexual-risk assessment — treat them as part of screening, not as a later social-work add-on. Sexual history changes HIV interval, STI testing, PrEP discussion, and whether “routine labs” missed hepatitis C in a person with ongoing injection-drug use.

Which authority belongs to which patient?

Use the right book for the age group:

• Adults and older adults: USPSTF for most cancer, cardiovascular, infectious, and behavioral screens.
• Infants, children, and most well-adolescent visits: AAP Bright Futures periodicity schedule. Pediatric well care is denser than USPSTF. Several pediatric items (structured autism screens, universal lipids at 9–11 and 17–21 years) are AAP/NHLBI, not USPSTF A/B recommendations.
• Immunizations: ACIP (CDC Advisory Committee on Immunization Practices), not USPSTF. Assessment means identifying who is due, documenting contraindications and catch-up, and knowing where to look. Full schedules live in the later immunization-planning section — do not dump infant series dates here.
• Specialty societies (ACOG, ACS, ACC/AHA) are often more aggressive than USPSTF. On ANCC items, default to USPSTF unless the stem names another guideline or the patient is clearly not average risk.

A concrete collision: USPSTF has an I statement for lipid screening in children and adolescents. Bright Futures/NHLBI still recommend universal lipids once at 9–11 years and once at 17–21, plus earlier targeted testing when family history or personal risk is present. Teach both, and name the source in your reasoning.

High-yield adult screens FNPs actually use (2024–2026)

If a recommendation date is in flux on exam day, do not invent a new start age. Teach the decision rule: population, test, interval, stop rule, grade.

Blood pressure. Screen adults 18 and older with office measurement (Grade A). Confirm elevated office readings with out-of-office measurement before you label hypertension. Bright Futures starts routine BP at age 3 in children.

Cervical cancer. Average-risk screening starts at 21, not at coitarche and not because HPV vaccination is complete. Ages 21–29: cytology alone every 3 years. Ages 30–65: cytology every 3 years, high-risk HPV every 5 years, or cotesting every 5 years. Stop after 65 when prior screening is adequate and there is no high-grade history (CIN2+). Do not screen after hysterectomy for benign disease if the cervix is gone. Screening before 21 is Grade D.

Colorectal cancer. Screen 45–75. Ages 50–75 are Grade A; 45–49 are Grade B — both mean offer the service. Ages 76–85 are Grade C (selectively offer). Acceptable strategies include annual FIT, stool DNA–FIT at the USPSTF-listed 1- to 3-year interval, sigmoidoscopy, or colonoscopy (commonly every 10 years after a normal average-risk exam). A positive stool test is a screen; colonoscopy is the diagnostic next step.

Lung cancer. Annual low-dose CT for adults 50–80 with a 20 pack-year history who currently smoke or quit within the past 15 years (Grade B). Pack-years = packs per day × years smoked. Stop after 15 smoke-free years, when a health problem limits life expectancy or candidacy for curative surgery, or at age 80. A 62-year-old who smoked 1 pack daily for 22 years and quit 16 years ago is not eligible.

Breast cancer. The April 2024 USPSTF final recommendation is biennial mammography for women 40–74 (Grade B). That replaced the older “start at 50, individualize 40–49” teaching point. Evidence is insufficient (I) for screening after 75 and for routine adjunctive ultrasound or MRI in average-risk women, including the dense-breast supplemental-imaging question. High genetic or lifetime risk leaves the average-risk pathway.

Depression and anxiety. Screen adults — including pregnant, postpartum, and older adults — for depression (Grade B, 2023). Screen for anxiety in adults 64 and younger, including perinatal patients (Grade B); evidence is insufficient (I) at 65 and older. In pediatrics, USPSTF supports anxiety screening at 8–18 years and depression screening at 12–18 years. A positive PHQ-2/PHQ-9 or GAD-7 requires diagnostic follow-up; it is not itself the diagnosis. Suicide-risk screening as a stand-alone USPSTF service remains an I statement in adults.

Unhealthy alcohol use. Screen adults 18 and older, including pregnant patients (Grade B), and provide brief behavioral counseling when unhealthy use is found. AUDIT-C or a validated single item fits either a focused or a comprehensive visit. USPSTF has an I statement for screening adolescents; Bright Futures still expects substance inquiry inside HEADSS.

HIV. Screen adolescents and adults 15–65 (Grade A) and all pregnant people. Screen outside that age band when risk is increased. After the initial screen, interval is risk-based; annual testing is reasonable for ongoing risk (new partners, STI, injection-drug use, PrEP care).

Hepatitis C. Screen adults 18–79 once (Grade B). Repeat when risk continues. A reactive antibody requires HCV RNA.

Statin for primary prevention (2022 USPSTF). For adults 40–75 with at least one CVD risk factor (dyslipidemia, diabetes, hypertension, or smoking) and a 10-year CVD risk of 10% or greater, initiate a statin (Grade B). If risk is 7.5% to <10% plus a risk factor, selectively offer (Grade C). Evidence is insufficient to start a statin for primary prevention at 76 or older (I). This is narrower than the 2018 ACC/AHA cholesterol guideline, which treats more people, including all adults 40–75 with diabetes. If the stem says USPSTF, do not start a statin for diabetes alone without the risk-factor-plus-risk-score frame.

Osteoporosis. Screen women 65 and older (Grade B; statement updated January 2025). Screen postmenopausal women younger than 65 when clinical risk is increased (prior fracture, long-term glucocorticoids, low body weight, parental hip fracture, smoking, excess alcohol). Do not invent a USPSTF start age for routine screening in men — evidence has been insufficient for a universal male Grade B.

Abdominal aortic aneurysm is previewed here because it is a population rule you will apply in the age-band section: one-time ultrasound in men 65–75 who have ever smoked (Grade B). Selectively offer to men 65–75 who never smoked (Grade C). Do not routinely screen women.

Putting the grade to work in one visit

Population screening is a workflow: identify the age/sex/risk stratum; pull the A/B items that apply; add Bright Futures or ACIP items for children; ask the SDOH and sexual-risk questions that change eligibility or follow-up; distinguish overdue screens from diagnostic tests the patient already needs for a symptom; close the loop on abnormal results.

Vignette. A 51-year-old woman is new, has never had colorectal screening, last Pap at 46, smokes 1 pack daily for 25 years (25 pack-years, still smoking), PHQ-2 is positive, and she missed two mammogram van days because she works nights and has no car. The assessment is not “order annual labs.” It is a panel of offers: colorectal strategy she can complete, cervical screening now, LDCT counseling and navigation, depression evaluation, office BP with a plan to confirm out of office, HIV and HCV if never done, tobacco treatment, and a transportation/insurance plan so the Grade B services can actually happen. That is population health promotion as an FNP skill.